Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A) for the treatment of uncomplicated malaria during second and third trimester pregnancy to oral Quinine hydrochloride. The PCR-corrected adequate clinical and parasitological response (ACPR) on day 42 is considered as the primary efficacy criterion. Newborns will be followed for growth and development indicators.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria

NCT00852423

Malaria in Pregnancy

COMPLETED PHASE3

Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy

NCT01054248

Malaria

COMPLETED PHASE3

Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children

NCT00540202

Uncomplicated Malaria

UNKNOWN PHASE4

Safety of Antimalarials in the FIRst trimEster

NCT06962319

Malaria, Pregnancy Malaria, Antepartum Malaria (Uncomplicated)

RECRUITING PHASE3

Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil

NCT01082731

Malaria

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Title:

Efficacy and Safety of Quinine vs Artemether/Lumefantrine in uncomplicated malaria during pregnancy, Mbarara, Uganda (2006/2007).

Regulatory Status:

Investigational - Phase IV

Investigational Product and route:

* Quinine hydrochloride, oral route.
* Coartem® (Novartis Pharma AG, Basel, Switzerland), oral route.

Lead Investigator and Study Centre Primary objective - To establish that, in pregnant women with uncomplicated Plasmodium falciparum malaria, the PCR-adjusted efficacy of Artemether/Lumefantrine is not inferior to oral Quinine.

Secondary objectives

* To define the pharmacokinetics of the combination artemether-lumefantrine (AL) in the treatment of uncomplicated P. falciparum infections in the last two trimesters of pregnancy.
* To collect baseline data on maternal, obstetric and infant outcomes.
* To estimate the incidence of malaria infection, both microscopic and sub-microscopic (by PCR) during pregnancy.
* women attending Mbarara National Referral Hospital (MNRH) ante-natal clinic (ANC).
* Women with a positive blood smear during follow-up will be invited to participate in a non-inferiority, open, randomised, non- inferiority trial comparing the efficacy and tolerance of Coartem® (Artemether-Lumefantrine) for the treatment of uncomplicated malaria during second and third trimester pregnancy to oral Quinine hydrochloride. PCR-corrected adequate clinical and parasitological response (ACPR) on day 42 is considered as the primary efficacy criterion.
* Women with uncomplicated malaria from the efficacy study, will be followed to obtain an efficacy endpoint at 42 days OR at delivery, whichever timepoint is the last.
* Newborns will be followed monthly up to the age of 1 year.

Inclusion Criteria (Efficacy Study):

* Pregnant woman
* Malaria infection, detected by microscopy, with P. falciparum (mixed or mono-infection)
* Age of gestation: 13 weeks and beyond
* Efficacy study signed informed consent form

Exclusion Criteria (Efficacy Study):

* P. falciparum parasitaemia above 250,000 parasites/μl
* Severe anaemia
* Signs or symptoms of severe/complicated malaria requiring parenteral treatment (WHO 2000)
* Known allergy to artemisinin derivatives, lumefantrine or quinine;
* Previous participation in the efficacy study
* Inability to attend the efficacy study follow-up schedule.

Study drugs and Administration

* Group 1 (Active Control): Quinine hydrochloride (10 mg/Kg/8h for 7 days) administered orally.
* Group 2 (Test): Coartem®, fixed Artemether-Lumefantrine (20/120 mg) GMP manufactured by Novartis Pharma AG (Basel, Switzerland), 4 tablets twice a day for 3 days with 200 ml of milk tea at each dose .

Endpoints

\- Primary efficacy endpoint: PCR-corrected adequate clinical and parasitological response (ACPR) on Day 42.

* Secondary efficacy endpoints:
* PCR-corrected(ACPR)at delivery
* Pharmacokinetic parameters
* Symptom clearance Time
* Proportion of patients who have fever cleared at Day 1, 2 and 3
* Safety endpoints:
* Incidence of any adverse events
* Pregnancy outcome
* Infant development during the first year of life

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Quinine

Group Type ACTIVE_COMPARATOR

Quinine

Intervention Type DRUG

Arthemeter lumefantrine

Group Type ACTIVE_COMPARATOR

artemether / lumefantrine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quinine

Intervention Type DRUG

artemether / lumefantrine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Cohort Study:

* Weeks of pregnancy between 13 and 22 weeks
* Resident in Mbarara Municipality (radius of 15km from MNRH)
* Cohort study signed informed consent form

Efficacy Study:

* Pregnant woman
* Malaria infection, detected by microscopy, with P. falciparum (mixed or mono-infection)
* Age of gestation: 13 weeks and beyond
* Efficacy study signed informed consent form

Exclusion Criteria

Efficacy Study:

* P. falciparum parasitaemia above 250,000 parasites/μl
* Severe anaemia
* Signs or symptoms of severe/complicated malaria requiring parenteral treatment (WHO 2000)
* Known allergy to artemisinin derivatives, lumefantrine or quinine;
* Previous participation in the efficacy study
* Inability to attend the efficacy study follow-up schedule.

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No